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ABSTRACT 
Objective: The aim of this study was to analyze the NP/OP S. pneumoniae serotype distribution and potential vaccine 
coverage in Costa Rican children with Otitis Media (OM) before the introduction of PCV-7 in the National Immuniza-
tion Program (NIP). Methods: Between 2002 and 2006, NP and OP samples were obtained from 641 children from 6 to 
79 months of age, at the time of OM diagnosis. S. pneumoniae serotyping and antimicrobial susceptibility were per-
formed. Results: 386 S. pneumoniae isolates were recovered. The most common S. pneumoniae serotypes (ST) were: 
ST 6B, ST 14, ST 19F. Penicillin non-susceptibility was observed among 57% of the isolates obtained from children < 
24 months of age. 15% strains were multidrug resistant. Potential vaccine coverage was: PCV-7: 60%; PCV-10: 62%; 
and PCV-13: 76% and against penicillin non-susceptible and multidrug resistant isolates was: PCV-7; 59% and 83%, 
respectively; PCV-10: 60% and 85%, respectively and PCV-13: 74% and 96%, respectively. Conclusions: S. pneumo-
niae was isolated from the NP and/or OP in the majority (59%) of studied children with OM. At a statistical significant 
level, only serotype 3 was more frequently isolated among children >24 months of age. Antibiotic non-susceptibility 
and MDR were significantly higher in children <24 months of age. This study demonstrates that PCV-13 offers the 
highest potential vaccine coverage and serves to assess the impact of introduction of one of the conjugated vaccines in 
the NIP in Costa Rica. 
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1. Introduction 
Streptococcus pneumoniae is a major cause of morbidity 
and mortality in children, especially in those younger 
than 5 years of age living in developing countries [1-3]. 
The main reservoirs of this bacterial pathogen are the 
nasopharynx (NP) and the oropharynx (OP), from which 
it can spread directly to adjacent mucosal tissues to cause 
otitis media (OM) or pneumonia, or through the blood 
stream to other sites causing sepsis, meningitis or dis- 
seminated focal infections. S. pneumoniae is usually iso- 
lated in 25% to 60% of NP cultures obtained from heal- 
thy children [1-6]. 
Nasopharyngeal colonization with S. pneumoniae is a 
pre-requisite for local and systemic disease. Several 
studies conducted in Israel [6], South Africa [7], Pakistan 
[8] and Brazil [9] confirm that nasopharyngeal coloniza- 
tion with S. pneumoniae in young children may predict 
the serotype distribution and antimicrobial susceptibility 
of the strains producing invasive disease. In a prospective 
study performed in Costa Rica, 79.2% of children in 
whom NP cultures were obtained weekly had at least one 
positive culture for S. pneumoniae during the first year of 
life [10]. 
Streptococcus pneumoniae carriage is highest among 
infants and young children (especially in those <24 
months of age) and decreases with age [11]. In the gen- *Currently Dr. Adriano Arguedas works at Pfizer Inc. 
Copyright © 2013 SciRes.                                                                                 WJV 
Streptococcus pneumoniae Upper Respiratory Carriage in Costa Rican Children with Otitis Media before  
the Introduction of the Heptavalent Conjugated Vaccine in the National Immunization Program 
40 
eral population in the United States and other industrial- 
ized countries, the mean age of S. pneumoniae acquisi- 
tion is approximately 6 months [12,13], whereas in de- 
veloping countries, it is as early as 2 to 3 months of age 
[14,15].  
During the past 15 years, a worldwide increase of an- 
timicrobial resistance by S. pneumoniae has been ob- 
served, particularly among strains colonizing the respi- 
ratory tract or producing respiratory tract infections [16- 
18]. Antibiotic-resistance involve mainly few serotypes 
(6A, 6B, 9V, 14, 19A, 19F and 23F).  
Numerous studies have shown that S. pneumoniae 
conjugate vaccines (PCVs) reduce nasopharyngeal car- 
riage of vaccine serotypes [19-27], however, concerns 
have been raised because of the increase of certain non- 
vaccine serotypes such as 19A, 7F and 3 following the 
introduction of PCV-7 into the NIP of different coun- 
tries [28,29].  
PCV-7 was introduced in Costa Rica in 2004 but its 
use was limited to high risk patients and the private sec- 
tor, until 2009 when it was introduced into the NIP (Na- 
tional Immunization Program). Based on the number of 
PCV-7 doses distributed, it is estimated that less than 5% 
of the annual birth cohort were fully vaccinated with 
PCV-7 before NIP introduction. 
Our main objectives in this study were 1) to analyze 
the prevalence and serotype distribution of S. pneumo- 
niae NP and/or OP colonization among Costa Rican 
children from 6 to 79 months of age, with OM before the 
introduction of PCV-7 in the NIP of Costa Rica; 2) ana- 
lyze the antimicrobial susceptibility patterns among the 
recovered NP and OP S. pneumoniae serotypes isolated; 
and 3) calculate the potential vaccine coverage against 
the isolated serotypes with the three currently available 
PCVs in Latin America (PCV-7, PCV-10 and PCV-13).  
2. Materials and Methods  
2.1. Study Population 
As part of various clinical trials of antimicrobial drug 
efficacy for OM conducted between 2002 and 2006, a 
total of 641 Costa Rican children, aged 6 - 79 months, 
with OM and in whom an NP and/or OP culture were 
obtained at the time of OM diagnosis, were included in 
the present analysis.  
Participants with at least one of the following ear 
finding were included in the current analysis: purulent 
otorrhea of <24 hour duration, at least one otoscopic 
signs of middle ear effusion: decreased or absent tym- 
panic membrane (TM) mobility; and at least one indica- 
tion of acute inflammation (ear, pain, marked redness of 
TM or distinct fullness or bulging TM) and clinical 
symptoms of OM (fever, tugging or irritability). Partici- 
pants were excluded from the analysis if the TM was 
perforated for ≥48 hours; if tympanic tubes were present; 
and if congenital craniofacial abnormalities or any 
known immunodeficiency were notified. 
All the study protocols were approved by an Institu- 
tional Review Board and informed consent was obtained 
from the parents or legal guardian of each study partici- 
pant before enrollment. 
2.2. Nasopharyngeal and Oropharyngeal  
Sampling 
NP and/or OP samples were obtained in every participant 
at the baseline visit. Samples were obtained following a 
deep swab in the NP or OP with a flexible pediatric cul- 
ture device (Copan Diagnostics Inc, Corona, CA©). Once 
NP and/or OP samples were collected, they were imme- 
diately placed in an Amies medium without charcoal 
(Copan Diagnostics Inc, Corona, CA©) and transferred to 
the Research Laboratory for processing. In patients in 
whom the same S. pneumoniae serotype was isolated 
from both NP and/or OP, only data from NP was in- 
cluded in the analysis.  
2.3. Microbiology 
NP and/or OP samples were inoculated onto regular 
blood agar, blood agar with 5µg of gentamicin, chocolate 
agar, McConkey agar and manitol salt agar for incuba- 
tion at 37˚C in 5% CO2 environment for 18 - 72 hours at 
the bacteriology units of the Centro de Investigaciones 
Clínicas in Costa Rica. If growth was present, identifica- 
tion was performed by standard procedures. S. pneumo- 
niae identification was performed following the Clinical 
Committee for Clinical Laboratory Standards by standard 
procedures [30].  
2.4. Antimicrobial Susceptibility 
Susceptibility testing for erythromycin and trimethoprim- 
sulfametoxazole (TMP/SMX) was done by Kirby-Bauer 
disk diffusion. Susceptibility testing for penicillin, cef- 
triaxone, levofloxacin, amoxicillin, amoxicillin-clavu- 
lanate (AM-CL), was determined by minimal inhibitory 
concentration (MIC) by means of the E-test (PDM Epsi- 
lometer, AB Biodisk, Solma, Sweden). Because of the 
characteristics of the strips and as recommended by the 
manufacturer, when the E-test method was used, MIC 
values intermediate between two marks were rounded up 
to the next higher 2-fold dilution. Interpretation of the 
results was performed according to the National Com- 
mittee for Clinical Laboratory Standards recommenda- 
tions [30].  
MIC50 was defined as the MIC of a given antimicro- 
bial drug that inhibited growth of 50% of the isolates, 
and MIC90 was defined as the MIC of a given antimicro- 
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bial drug that inhibited growth of 90% of the isolates. S. 
pneumoniae isolates with an MIC ≤ 0.06 mg/L were con- 
sidered susceptible to penicillin; isolates with a MIC 
value between 0.125 mg/L and 1.0 mg/L were considered 
intermediate to penicillin and those with a MIC value ≥ 
2.0 mg/L were defined as penicillin resistant. 
Multidrug resistant (MDR) isolates were defined as 
those strains resistant to ≥3 different antimicrobial class- 
es. 
2.5. Streptococcus pneumoniae Serogrouping  
and Serotyping  
Initially all isolates were stored at −70˚C at Centro de 
Investigaciones Médicas in Costa Rica in Micro Bank 
vials (Pro-Laboratory Diagnostics, Austin, TX) and then 
shipped on dry ice or on transport media at room tem- 
perature to the Research Laboratory of the Pediatric In- 
fectious Diseases Unit at Soroka University Medical 
Center, Beer-Sheva, Israel. Serogrouping and serotyping 
of all S. pneumoniae isolates were performed in Beer- 
Sheva Israel by the Quellung reaction with antisera from 
Statens Serum Institute, Copenhagen, Denmark [31].  
2.6. Statistical Analysis  
The statistical package EPI INFO (version 3.5.3) was 
used to test difference on S. pneumoniae serotyping dis- 
tribution and microbial susceptibility between children 
aged ≤ 24 months and >24 months (by the Fisher exact 
test, Yates or square test, as appropriate). A P value of < 
0.05 was considered significant. 
Proportion of coverage by PCV-7, PCV-10 and PCV- 
13 were calculated by proportion of serotypes included in 
the vaccines of all serotypes detected in children. No 
cross protection between serotypes was assumed.  
3. Results 
Between 2002 and 2006, simultaneous NP and OP sam- 
ples were obtained from 641 Costa Rican children with 
OM. The mean age ± standard deviation (SD) was 23 
months ± 16.5 months and 393 (61%) children were ≤24 
months old. Among the 641 children, a total of 386 S. 
pneumoniae isolates were detected from 376 (59%) 
participants (223/376 [59%] ≤ 24 months and 153/376 
[41%] > 24 months (P < 0.001)). Among the 386 isolates 
obtained, 359 (93%) were isolated from NP samples, 22 
(6%) were isolated from OP (P < 0.05) and 5 (1%) were 
isolated in both reservoirs but had a different serotype 
isolates.  
Among the 386 positive NP or OP samples, 229 (59%) 
samples were obtained among children ≤ 24 months of 
age (mean age: 13 months) and 157 (41%) samples were 
from children > than 24 months of age (mean age: 35 
months) (P < 0.001).  
3.1. Streptococcus pneumoniae Serotypes  
Among the 386 S. pneumoniae isolates, 346 (90%) were 
serotyped. Table 1 shows the distribution of S. pneumo- 
niae serotypes identified. Of the identified serotypes, 
only serotype 3 was significantly different between the 
age groups. Overall cumulative PCV-13 serotypes and 
non-PCV13 serotypes were different between the age 
groups. As a group, non-PCV13 serotypes were more 
common in the younger age group than in children >24  
 
Table 1. S. pneumoniae serotype distribution among isolates 
obtained from the nasopharynx and/or oropharynx in Costa 
Rican children with otitis media, between years 2002 and 
2006, according to age group. 
Total number of  
serotyped  
S. pneumoniae strains
Age group ≤ 24 
months 
Age group > 24 
months P value
346 203 143  
PCV-7 serotypes 
4 3 (1.5)a 3 (2.1) 0.6 
14 22 (10.8) 19 (13.3) 0.5 
19 F 46 (22.7) 29 (20.3) 0.6 
23 F 13 (6.4) 17 (11.9) 0.1 
6B 29 (14.3) 14 (9.8) 0.2 
9V 3 (1.5) 5 (3.5) 0.2 
18C 4 (2) 2 (1.4) 1 
Cumulative number of 
isolates included in 
PCV 7 
120 (59.1) 89 (62.2) 0.6 
PCV-10 serotypes 
1 1 (0.5) 1 (0.7) 1 
5 0 (0) 1 (0.7) 0.2 
7F 1 (0.5) 0 (0) 0.2 
Cumulative number of 
isolates included in 
PCV 10 
122 (60.1) 91 (63.6) 0.5 
PCV-13 serotypes 
3 11 (5.4) 18(12.6) 0.03 
6A 9 (4.4) 6 (4.2) 0.8 
19A 3 (1.5) 2 (1.4) 1 
Cumulative number of 
isolates included in 
PCV 13 
145 (71.4) 117 (81.8) 0.03 
Nonvaccine serotypes isolated 
13, 28, 34, 48, 10A, 10B, 
11A, 11F, 15A, 15B,15C, 
15B/C, 16F, 17F, 18A, 
18F, 19V, 35B, 35F, 6C, 
9A, 9L, 9N, 24F, 38, 45B
58 (28.6) 26 (18.2) 0.04 
aNumbers in parentheses, percent. 
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months old. 
3.2 Antimicrobial Susceptibility  
Minimal inhibitory concentration (MIC) values for the 
different antimicrobials tested among S. pneumoniae 
serotypes included in the three conjugated vaccines are 
shown in Table 2. Children ≤24 months (203/346 [59%]) 
had statistically significantly more antimicrobial non-sus- 
ceptible isolates than children >24 months of age (143/ 
346 [41%]) (P < 0.001).  
Penicillin non-susceptibility serotypes included in the 
three conjugated S. pneumoniae vaccines (PCV-7, PCV- 
10 and PCV-13) were: 57% in children ≤ 24 months 
versus a 38% in older children (P < 0.001). 
3.3. Multidrug Resistance (MDR) 
Among the 346 serotyped isolates, 53 (15%) strains be-
longing to only 10 serotypes were considered MDR: 4% 
(2/53) of these MDR strains were non-PCV 13 serotypes 
and 96% (51/53) were PCV-13 (P < 0.001), Table 3 de- 
scribes the MDR vaccine-type distribution and their an- 
timicrobial resistance. 
3.4. Potential Vaccine Coverage  
Potential coverage with the conjugated vaccines, PCV-7, 
PCV-10 and PCV-13, for the overall study population 
was: 60%, 62% and 76% respectively, with PCV-13 
showing statistical significantly increased vaccine cov- 
erage than that observed with PCV-7 (P < 0.001) or 
PCV-10 (P < 0.001).  
Potential vaccine coverage against penicillin non-sus- 
ceptible isolates was as follows: PCV-7: 59%, PCV-10: 
60% and PCV-13: 74% (PCV-7 vs. PCV-10: P: 0.8; 
PCV-10 vs. PCV-13: P < 0.001; PCV-7 vs. PCV-13: P < 
0.001). Potential vaccine coverage against MDR sero- 
types were as follows: PCV-7: 44/53 (83%), PCV-10: 
45/53 (85%) and PCV-13: 51/53 (96%) (PCV-7 vs. 
PCV-10: P: 0.8; PCV-10 vs. PCV-13: P: 0.04; PCV-7 vs. 
PCV-13: P: 0.03). 
4. Discussion 
Streptococcus pneumoniae is the most common cause of 
vaccine preventable death in children less than 5 years of 
age globally. In Costa Rica, it is also the most frequent 
pathogen detected in patients with OM [32].  
In the present study, S. pneumoniae colonization of the 
upper respiratory tract in children with OM was analyzed, 
59% of the patients harbor this isolate in the NP or OP. 
Similar to previous studies, this study demonstrates that the 
vast majority of colonizing strains were isolated from the 
NP in comparison to the OP (93% versus 7%, respec-  
 
Table 2. Minimal inhibitory concentration (μg/ml) values among vaccine-type Streptococcus pneumoniae strains isolated from 
the nasopharynx and or oropharynx of Costa Rican children with otitis media, during 2002-2006. 
Amoxicillin AM-CL Ceftriaxone Levofloxacin Penicillin 
PCV-7 Serotypes SEROTYPES 
Na MIC50b MIC90c N MIC50 MIC90 N MIC50 MIC90 N MIC50 MIC90 N MIC50 MIC90
4 6 0.125 0.125 6 0.125 0.125 6 0.125 0.125 6 0.500 1.000 6 0.125 0.125
6B 42 0.125 0.125 42 0.125 0.125 42 0.125 0.125 42 0.500 1.000 42 0.125 0.125
9V 8 0.125 0.125 8 0.125 0.125 8 0.125 0.125 8 0.500 1.000 7 0.125 0.125
14 41 0.125 0.125 41 0.125 0.125 41 0.125 0.250 40 1.000 1.000 41 0.125 0.125
18C 6 0.125 1.0 6 0.125 1 6 0.125 0.500 6 1.000 1.000 6 0.125 2.000
19F 74 0.125 1.0 74 0.125 1 74 0.125 1.000 74 1.000 1.000 73 0.125 2.000
23F 30 0.125 1.0 30 0.125 2.0 30 0.250 2.000 30 1.000 1.000 30 1.000 2.000
PCV-10 Serotypes 
1 2 0.125 0.125 2 0.125 0.125 2 0.125 0.125 2 0.500 0.500 2 0.125 0.125
5 1 0.125 0.125 1 0.125 0.125 1 0.125 0.125 1 1.000 1.000 1 0,125 0.125
7F 1 0.125 0,125 1 0.125 0.125 1 0.125 0.125 1 0.500 0.500 1 0.125 0.125
PCV-13 Serotypes 
19A 4 0.125 1.000 4 0.125 1.000 4 0.125 1.000 4 1.000 1.000 4 0.125 2.000
3 27 0.125 0.125 27 0.125 0.125 27 0.125 0.125 27 0.500 0.500 27 0.125 0.125
6A 15 0.125 0.125 15 0.125 0.125 15 0.125 0.125 15 0.500 1.000 15 0.125 0.125
aNumber of isolates tested; bMinimal inhibitory concentration for 50% of the strains; cMinimal inhibitory concentration for 90% of the strains. 
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Table 3. Multidrug resistance among vaccine-type Streptococcus pneumoniae strains isolated from the nasopharynx and/or 
oropharynx of Costa Rican children with otitis media, during 2002-2006. 
MDR*S. pneumoniae serotype Total number of S. pneumoniae strains isolated per serotype 
Total number of MDRa 
S. pneumoniae strains  
MDR  
percentage 
Antimicrobial  
resistance 
19A 5 3 60% 
Penicillin 
Amoxicillin 
AM-CL 
Ceftriaxone 
Erythromycin 
TPM/SMX 
1 2 1 50% 
Penicillin  
Erythromycin  
TMP/SMX 
14 41 19 46% 
Ceftriaxone  
Penicillin  
Erythromycin  
TMP/SMX 
9V 8 2 25% 
Ceftriaxone  
Penicillin 
TMP/SMX 
6A 15 3 20% 
Penicillin  
Ceftriaxone  
Erythromycin  
TMP/SMX 
6B 43 8 19% 
Penicillin  
Erythromycin  
TMP/SMX 
19F 75 12 16% 
Ceftriaxone  
Penicillin 
Erythromycin 
TMP/SMX 
23F 30 3 10% 
Ceftriaxone  
Penicillin  
Erythromycin  
TMP/SMX 
aMDR: Multi-Drug Resistant Isolates. 
 
tively; P < 0.001), but that 7% of isolates would have 
been missed if OP cultures were not performed [33-37].  
Incidence of colonization, mucosal and invasive dis- 
ease caused by S. pneumoniae varies by gender, season 
and age group [36]. In our study and as previously de- 
scribed in other studies [5,6,10,36], children <24 months 
of age had significantly higher rates of S. pneumoniae 
colonization than children older than 24 months (59% 
versus 41%, respectively; P < 0.001). The most common 
NP and/or OP S. pneumoniae serotypes obtained in this 
group of Costa Rican children with OM were: 19F, 6B, 
14, 23F and 3, comprising 59.6% of the total strains se- 
rotyped. The current analysis indicates that in Costa Rica, 
during the study period, the most frequent colonizing 
serotype isolated from children at all ages with OM was 
serotype 19F. These data correlates with previous studies 
performed in Costa Rican children since 1999 where 
serotype 19F was also the most common serotype iso- 
lated from the middle ear fluid of children with OM [32- 
36,38].  
The individual serotype distribution was similar 
among age groups, except for serotype 3, which was sig- 
nificantly more frequent among children >24 months of 
age than among children ≤ than 24 months of age. Sero- 
types isolated in children <24 months of age had a statis- 
tically significant higher rate of penicillin resistance than 
those from children >24 months of age. The higher an- 
timicrobial resistance rates in the younger population is 
similar to previous studies [17-19,21] and also correlates 
with higher resistance rates observed in S. pneumoniae 
strains obtained from the middle ear fluid from children 
≤ 24 months of age, and supports the need for pneumo- 
coccal conjugate vaccination in this age group [6,35,36].  
Although serotype 19A was not a frequent pathogen 
during the study period (5 isolates), it was the most fre-
quent MDR serotype (60%).  
Overall potential vaccine protection against the NP 
and/or OP S. pneumoniae serotypes isolated in this study 
from Costa Rican children with OM were higher with 
PCV13 (76%) than that with PCV-10 (62%) or PCV-7 
(60%). This difference was mainly driven by the fre-  
quency of serotype 3 and the small numbers of serotypes 
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1, 5, 19A and 7F found. This parallels the serotypes 
found in OM where serotype 3 is frequent and serotypes 
1 and 5 are rarely found as causes of OM, although they 
can cause invasive disease. 
PCV-13 also showed higher serotype coverage rates 
against penicillin-resistant strains and MDR strains (74% 
and 96%, respectively) than PCV-10 (60% and 85%, 
respectively) and PCV-7 (59% and 83% respectively). 
To our knowledge, this study represents the largest 
Latin America set of data analyzing the distribution of S. 
pneumoniae serotypes obtained from the NP and/or OP 
of children with OM before the introduction of PCV-7 
into the NIP of Costa Rica and following a limited use of 
PCV-7 into a limited cohort of children. This study serv- 
es as a baseline for evaluation of impact of the introduc- 
tion of PCVs into the Costa Rican NIP.  
Currently, three PCVs are in use in Latin America 
(PCV-7, PCV-10 and PCV-13). Our data analyzing the 
serotype distribution of S. pneumoniae serotypes colo- 
nizing the NP and/or OP of Costa Rican children with 
OM suggest that, similar to the analysis performed 
among middle ear fluid isolates in the same population 
[39], PCV-13 offers the broadest protection against S. 
pneumoniae strains isolated in this population.  
Following the introduction of PCV-13 into the NIP of 
Costa Rica in 2011, further studies will evaluate the S. pneu- 
moniae serotype dynamics and antimicrobial susceptibil- 
ity patterns in the NP and/or OP of Costa Rican children.  
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